Article thumbnail
Location of Repository

Anticomplement therapy

By Prathit A Kulkarni and Vahid Afshar-Kharghan

Abstract

The complement system is an important part of innate immunity; however, as with other parts of the immune system, the complement system can become pathologically activated and create or worsen disease. Anticomplement reagents have been studied for several years, but only recently have they emerged as a viable therapeutic tool. Here, we describe the role of the complement system in a wide array of diseases, as well as the use of anticomplement therapy as treatment for these diseases in animal models and in human clinical trials. Specifically, we will discuss the role of anticomplement therapy in paroxysmal nocturnal hemoglobinuria, glomerulonephritis, and heart disease, including coronary artery disease, myocardial infarction, and coronary revascularization procedures such as percutaneous coronary angioplasty and coronary artery bypass graft surgery

Topics: Review
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:2727911
Provided by: PubMed Central

Suggested articles

Citations

  1. (2007). 70:71–86.Biologics: Targets & Therapy 2008:2(4) 683 Anticomplement therapy Engström
  2. (2006). A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related macular degeneration.
  3. (2000). A recombinant soluble chimeric complement inhibitor composed of human CD46 and CD55 reduces acute cardiac tissue injury in models of pig-to-human heart transplantation.
  4. (1997). A soluble chimeric complement inhibitory protein that possesses both decay-accelerating and factor I co-factor activities.
  5. (1984). Accumulation of IgG and complement factor C3 in human arterial endothelium and atherosclerotic lesions.
  6. (2006). Administration of C1-esterase inhibitor during emergency coronary artery bypass surgery in acute ST-elevation myocardial infarction.
  7. (1998). Age-related macular degeneration. Clinical features in a large family and linkage to chromosome 1q. Arch Ophthalmol,
  8. (1996). Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specifi c for complement component C5.
  9. (2006). Anti-apoptotic role for C1 inhibitor in ischemia/reperfusion-induced myocardial cell injury.
  10. (2001). Anti-C1q antibodies may help in diagnosing a renal fl are in lupus nephritis.
  11. (2006). Anti-ischemia/reperfusion of C1 inhibitor in myocardial cell injury via regulation of local myocardial C3 activity.
  12. (1995). Association of serum C3 levels with the risk of myocardial infarction.
  13. (2007). Attenuation of myocardial reperfusion injury in pigs by Mirococept, a membrane-targeted complement inhibitor derived from human CR1. Cardiovasc Res,
  14. (2007). Benefi cial effects of C1 esterase inhibitor in ST-elevation myocardial infarction in patient who underwent surgical reperfusion: a randomised double-blind study.
  15. (2007). Benefi cial effects of complement inhibition with soluble complement receptor 1 (TP10) during cardiac surgery: is there a gender difference? Circulation,
  16. (2003). C-reactive protein activates complement in infarcted human myocardium.
  17. (1999). C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction.
  18. (2002). C1q defi ciency and autoimmunity: the effects of genetic background on disease expression.
  19. (1976). C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase.
  20. (2002). C5a is important in the tubulointerstitial component of experimental immune complex glomerulonephritis. Clin Exp Immunol,
  21. (2005). C5a promotes development of experimental lupus nephritis which can be blocked with a specifi c receptor antagonist.
  22. (1995). Cardioprotective effects of a C1 esterase inhibitor in myocardial ischemia and reperfusion.
  23. (2003). CD59a defi ciency exacerbates accelerated nephrotoxic nephritis in mice.
  24. (2006). CFH haplotypes without the Y402H coding variant show strong association with susceptibility to age-related macular degeneration.
  25. (2006). Colocalisation of intraplaque C reactive protein, complement oxidised low density lipoprotein, and macrophages in stable and unstable angina and acute myocardial infarction.
  26. (2006). Common variation in three genes, including a noncoding variant in CFH, strongly infl uences risk of age-related macular degeneration.
  27. (1982). Complement activation by C-reactive protein complexes.
  28. (2005). Complement activation in acute coronary syndromes.
  29. (2001). Complement analysis in children with idiopathic membranoproliferative glomerulonephritis: a long-term follow-up. Pediatr Allergy Immunol,
  30. (2005). Complement and the kidney: what the nephrologist needs to know in 2006? Nephrol Dial Transplant,
  31. (1997). Complement C5a, TGF-beta 1, and MCP-1, in sequence, induce migration of monocytes into ischemic canine myocardium within the fi rst one to fi ve hours after reperfusion.
  32. (2005). Complement component C5a predicts future cardiovascular events in patients with advanced atherosclerosis.
  33. (2007). Complement factor H defi ciency in aged mice causes retinal abnormalities and visual dysfunction.
  34. (2005). Complement factor H polymorphism and age-related macular degeneration.
  35. (2005). Complement factor H polymorphism in age-related macular degeneration.
  36. (2005). Complement factor H variant increases the risk of age-related macular degeneration.
  37. (1980). Complement localization and mediation of ischemic injury in baboon myocardium.
  38. (1989). Complement receptors and regulatory proteins in human atherosclerotic lesions.
  39. (2003). Complement therapeutics; history and current progress. Mol Immunol,
  40. (2002). Complementinduced impairment of innate immunity during sepsis.
  41. (2006). Concerning the mechanism of pexelizumab’s benefi t in acute myocardial infarction.
  42. (2002). Continuous 48-h C1-inhibitor treatment, following reperfusion therapy, in patients with acute myocardial infarction.
  43. (2002). Coupling complement regulators to immunoglobulin domains generates effective anti-complement reagents with extended half-life in vivo. Clin Exp Immunol,
  44. (1989). Decay accelerating factor is expressed on vascular smooth muscle cells in human atherosclerotic lesions.
  45. (2007). Decay-accelerating factor but not CD59 limits experimental immune-complex glomerulonephritis. Lab Invest,
  46. (1968). Decomplementization by a factor extracted from cobra venom. Effect on several immune reactions of the guinea pig and rat. Ann Inst Pasteur Paris,
  47. (1993). Defi ciency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria.
  48. (1970). Depletion of plasma complement in vivo by a protein of cobra venom: its effect on various immunologic reactions.
  49. (1988). Detection of the terminal complement complex in patient plasma following acute myocardial infarction.
  50. (2003). Diagnostic and prognostic signifi cance of anti-C1q antibodies in systemic lupus erythematosus. Curr Opin Nephrol Hypertens,
  51. (1997). Duraflo II coating of cardiopulmonary bypass circuits reduces complement activation, but does not affect the release of granulocyte enzymes: a European multicentre study.
  52. (2002). Eculizumab (C5a complement inhibitor) in the treatment of idiopathic membranous nephropathy [abstract].
  53. (1967). Effect of cobra venom-induced inhibition of complement activity on allograft and xenograft rejection reactions.
  54. (2004). Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria.
  55. (2004). Effect of neutralizing antibodies to IL-10 and C5 on the renal damage caused by a pathogenic human anti-dsDNA antibody. Rheumatology (Oxford ),
  56. (2006). Effect of pexelizumab in coronary artery bypass graft surgery with extended aortic cross-clamp time. Ann Thorac Surg,
  57. (2006). Effect of pexelizumab on mortality in patients with acute myocardial infarction or undergoing coronary artery bypass surgery: a systematic overview.
  58. (2003). Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fi brinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial.
  59. (2007). Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria.
  60. (1996). Engineering of recombinant soluble CD46: an inhibitor of complement activation.
  61. (2007). Evidence for association between multiple complement pathway genes and AMD. Genet Epidemiol,
  62. (2002). Evidence for complement activation in ruptured coronary plaques in acute myocardial infarction.
  63. (1973). Formation and function of a complex of the C3 proactivator with a protein from cobra venom.
  64. (2007). Function and regulation of the complement system in cardiovascular diseases. Front Biosci,
  65. (2002). Fundamentals of reperfusion injury for the clinical cardiologist.
  66. (1991). FUT-175 as a potent inhibitor of C5/C3 convertase activity for production of C5a and C3a. Immunol Lett,
  67. (2006). High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis. Nephrol Dial Transplant,
  68. (2006). High serum C3 predicts poor outcome in IgM nephropathy. Nephron Clin Pract,
  69. (2006). His-384 allotypic variant of factor H associated with age-related macular degeneration has different heparin binding properties from the non-disease-associated form.
  70. (1992). Human recombinant soluble decay accelerating factor inhibits complement activation in vitro and in vivo.
  71. (1985). Immunoglobulins and complement components in human aortic atherosclerotic intima.
  72. (2004). Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass. Ann Thorac Surg,
  73. (2005). Improvement in the symptoms of smooth muscle dystonia during eculizumab therapy in paroxysmal nocturnal hemoglobinuria.
  74. (2002). Increased C5a receptor expression in sepsis.
  75. (2006). Infl ammation, complement activation and endothelial function in stable and unstable coronary artery disease.
  76. (2006). Inhibition of complement activation by pexelizumab reduces death in patients undergoing combined aortic valve replacement and coronary artery bypass surgery.
  77. (1996). Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol,
  78. (2007). Inhibition of complement factor C5 protects against anti-myeloperoxidase antibody-mediated glomerulonephritis in mice.
  79. (1996). Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library.
  80. (1991). Inhibition of terminal complement complex formation and cell lysis by monoclonal antibodies. Complement Infl amm,
  81. (1982). Inhibition of various immunological reactions in vivo by a new synthetic complement inhibitor. Int Arch Allergy Appl Immunol,
  82. (1974). Interaction of C-reactive protein complexes with the complement system. I. Consumption of human complement associated with the reaction of C-reactive protein with pneumococcal C-polysaccharide and with the choline phosphatides, lecithin, and sphingomyelin.
  83. (1974). Interaction of C-reactive protein complexes with the complement system. II. Consumption of guinea-pig complement by CRP complexes: requirement for human Clq.
  84. (1974). Interactions of C-reactive protein with the complement system. I. Protamine-induced consumption of complement in acute phase sera.
  85. (1971). Isolation of the anticomplementary protein from cobra venom and its mode of action on C3.
  86. (1992). Kinetics of C5a release in cardiac lymph of dogs experiencing coronary artery ischemia-reperfusion injury. Circ Res,
  87. (1992). Localization of sites through which C-reactive protein binds and activates complement to residues 14–26 and 76–92 of the human C1q A chain.
  88. (1992). Loss of expression of protectin (CD59) is associated with complement membrane attack complex deposition in myocardial infarction.
  89. (2007). Mechanisms of disease: the complement system in renal injury – new ways of looking at an old foe. Nat Clin Pract Nephrol,
  90. (2007). Mesangial immune complex glomerulonephritis due to complement factor D defi ciency.
  91. (1978). Modulation of the formation of the amplifi cation convertase of C3b, Bb, by native and commercial heparin.
  92. (1998). Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inhibition by anti-C5 therapy.
  93. (1995). Natural history of paroxysmal nocturnal hemoglobinuria.
  94. (1981). New synthetic inhibitors of C1r, C1 esterase, thrombin, plasmin, kallikrein, and trypsin.
  95. (1994). Paroxysmal nocturnal hemoglobinuria (PNH) is caused by somatic mutation in the PIG-A gene.
  96. (1996). Paroxysmal nocturnal hemoglobinuria: Long-term follow-up and prognostic factors. French society for haematology.
  97. (2007). Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial.
  98. (2006). Pexelizumab reduces death and myocardial infarction in higher risk cardiac surgical patients. Ann Thorac Surg,
  99. (2003). Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement Inhibition
  100. (1999). Pharmacology and biological effi cacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass.
  101. (1983). Polyions regulate the alternative amplifi cation pathway of complement.
  102. (2004). Preliminary report of the effects of complement suppression with pexelizumab on neurocognitive decline after coronary artery bypass graft surgery.
  103. (2006). Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-defi cient mice.
  104. (2005). Prognostic signifi cance of blood markers of infl ammation in patients ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial.
  105. (2006). Protection of erythrocytes from human complement-mediated lysis by membrane-targeted recombinant soluble CD59: a new approach to PNH therapy.
  106. (2002). Protection of innate immunity by C5aR antagonist in septic mice.
  107. (2001). Protective effects of anti-C5a peptide antibodies in experimental sepsis.
  108. (2007). Recent advances in the diagnosis, monitoring, and management of patients with paroxysmal nocturnal hemoglobinuria.
  109. (2007). Recent developments in the understanding and management of paroxysmal nocturnal hemoglobinuria.
  110. (2000). Recombinant human complement C5a receptor antagonist reduces infarct size after surgical revascularization.
  111. (1990). Recombinant soluble CR1 suppressed complement activation, infl ammation, and necrosis associated with reperfusion of ischemic myocardium. Trans Assoc Am Physicians,
  112. (1978). Reduction by cobra venom factor of myocardial necrosis after coronary artery occlusion.
  113. (2000). Relationship of serum C3 to fasting insulin, risk factors, and previous ischaemic events in middle-aged men.
  114. (2004). Respective roles of decay-accelerating factor and CD59 in circumventing glomerular injury in acute nephrotoxic serum nephritis.
  115. (2007). Role of complement in immune regulation and its exploitation by virus. Viral Immunol,
  116. (2008). Role of the complement in experimental sepsis.
  117. (2004). ScFv-mediated in vivo targeting of DAF to erythrocytes inhibits lysis by complement. Mol Immunol,
  118. (2005). Serum C-reactive protein and complement proteins in patients with acute myocardial infarction. Immunopharmacol Immunotoxicol,
  119. (2007). Serum complement C3/C4 ratio, a novel marker for recurrent cardiovascular events.
  120. (1903). Snake venom in relation to hemolysis, bacteriolysis and toxicity.
  121. (1993). Soluble complement receptor type 1 inhibits the complement pathway and prevents contractile failure in the postischemic heart. Evidence that complement activation is required for neutrophil-mediated reperfusion injury.
  122. (2004). Soluble human complement receptor 1 limits ischemic damage and cardiac surgery patients at high risk requiring cardiopulmonary bypass. Circulation, 110(11 Suppl 1):II274–9.
  123. (1990). Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis.
  124. (1979). Soluble proteins in the human atherosclerotic plaque. With spectral reference to immunoglobulins, C3 complement component, alpha 1 antitrypsin and alpha 2 macroglobulin.
  125. (2001). Specific inhibition of the classical complement pathway by C1q-binding peptides.
  126. (1970). Studies on a hemolytic factor of cobra venom requiring a heat-labile serum factor. Biochim Biophys Acta,
  127. (1975). Studies on the inhibition of C56-induced lysis (reactive lysis). VI. Modulation of C56-induced lysis polyanions and polycations.
  128. (2005). Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria.
  129. (1999). Targeting of functional antibody-CD59 fusion proteins to a cell surface.
  130. (2001). Targeting of functional antibody-decay-accelerating factor fusion proteins to a cell surface.
  131. (2004). Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial.
  132. (1983). The binding properties of human complement component C1q. Interaction with mucopolysaccharides.
  133. (2006). The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.
  134. (1990). The complement system in ischemic heart disease.
  135. (2006). The complement system in liver diseases. Cell Mol Immunol,
  136. (1995). The effects of soluble recombinant complement receptor 1 on complement-mediated experimental glomerulonephritis.
  137. (1978). The reaction between the complement subcomponent C1q, IgG complexes and polyionic molecules.
  138. (1982). The stunned myocardium: prolonged, post-ischemic ventricular dysfunction.
  139. (2006). The third component of the complement (C3) is a marker of the risk of atherogenesis.
  140. (1999). Total complement inhibition: an effective strategy to limit ischemic injury during coronary revascularization on cardiopulmonary bypass.
  141. (2005). Treatment of glomerulonephritis: will we ever have options other than steroids and cytotoxics? Kidney Int,
  142. (2002). Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice defi cient in complement factor
  143. (2006). Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration.
  144. (2004). Vascular ischaemia and reperfusion injury.
  145. (2007). Y402H polymorphism of complement factor H affects binding affi nity to C-reactive protein.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.